within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02A_Antacids.A02AB01_AluminiumHydroxide;
model AluminiumHydroxide 
   extends Pharmacolibrary.Drugs.ATC.A.A02AB01;

  annotation(Documentation(
    info ="<html><body><p>Aluminium hydroxide is an inorganic compound commonly used as an antacid for the symptomatic relief of heartburn, acid indigestion, and peptic ulcers. It works by neutralizing excess stomach acid. It has also been used as a phosphate binder in patients with chronic kidney disease, though this use has declined due to potential toxicity. It is an approved and widely used over-the-counter medication.</p><h4>Pharmacokinetics</h4><p>No formal published pharmacokinetic model parameters are available for aluminium hydroxide in humans, as absorption from the gastrointestinal tract is minimal and it acts locally in the stomach. The following estimates are provided based on general knowledge of the drug's pharmacology and information from non-specific sources.</p><h4>References</h4><ol><li><p>Ritter, W, et al., &amp; Baykal, N (1985). Pharmacokinetics of muzolimine after oral administration with and without aluminium hydroxide in healthy volunteers. <i>Zeitschrift fur Kardiologie</i> 74 Suppl 2 149–151. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/4002791/&quot;>https://pubmed.ncbi.nlm.nih.gov/4002791</a></p></li><li><p>Patel, G, et al., &amp; Talley, AK (2023). Effect of an Antacid (Aluminum Hydroxide/Magnesium Hydroxide/Simethicone) or a Proton Pump Inhibitor (Omeprazole) on the Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) in Healthy Adult Subjects. <i>Antimicrobial agents and chemotherapy</i> 67(4) e0149522–None. DOI:<a href=&quot;https://doi.org/10.1128/aac.01495-22&quot;>10.1128/aac.01495-22</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36943038/&quot;>https://pubmed.ncbi.nlm.nih.gov/36943038</a></p></li><li><p>Scott, G, et al., &amp; Rordorf, C (2004). Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. <i>Clinical pharmacokinetics</i> 43(5) 341–348. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200443050-00006&quot;>10.2165/00003088-200443050-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15080766/&quot;>https://pubmed.ncbi.nlm.nih.gov/15080766</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end AluminiumHydroxide;
